My studies focus on developing platforms to screen therapeutic peptides (GPCR-targeting), small molecules (enzyme-activating), and mRNA (immune cell-enhancing). This is achieved by integrating droplet-based microfluidic synthesis, single-cell functional analysis, and high-throughput screening. The overarching aim of my work is to accelerate drug discovery for neurological, metabolic, and oncological diseases.